Notizie aziendali
Questi comunicati stampa sono intesi come informazioni di riferimento per investitori e giornalisti statunitensi. Le informazioni contenute in ogni rassegna stampa sono aggiornate al momento della pubblicazione e KCI non si assume alcuna responsabilità per il loro aggiornamento in modo da riflettere gli sviluppi successivi.
KCI's LifeCell™ Corporation and Novadaq Technologies Enter North American Sales and Marketing Agreement for Exclusive Distribution of SPY® Imaging System
Prevena™ Incision Management System now available to all U.S. hospitals
New KCI Product Designed to Manage Incisions Following Surgery, Such as General, OB/GYN, Orthopedic, Cardiac Procedures
Prevena™ Incision Management System now available to all U.S. hospitals
KCI Obtains Favorable Ruling in German Patent Case
Court Finds Smith & Nephew's Renasys EZ Product Infringes KCI Patent; Issues Injunction
KCI Obtains Injunction against Smith & Nephew in United Kingdom
UK High Court of Justice Enters Injunction Against Smith & Nephew’s NPWT Products; Injunction Stayed Pending Expedited Appeal
KCI Boosts Research and Development Capabilities with Launch of Advanced Research and Technology Center
Innovation Center to Accelerate Company Mission of Making Healing Possible; New Organization Will Fuel Product Development and Commercialization
KCI Wins UK Patent Case Against Smith & Nephew
UK High Court of Justice Finds Smith & Nephew's Products Infringe Two NPWT Patents Exclusively Owned By KCI
KCI Prevena™ Incision Management System Licensed by Health Canada
Designed to Help Manage Patients' Incisions Successfully Following Surgery
KCI Receives FDA Clearance for Prevena™ Incision Management System
Postsurgical Incision Management Represents $1 Billion Global Market Opportunity: U.S. Approval Follows Prevena™ System Launch in Europe and Canada
KCI First Manufacturer to Commit to Submitting Product Labeling for FDA Medical Device Home Use Initiative
Move Signals KCI's Support of FDA's Goal of Ensuring Strong Standards for Patient Home Use
KCI Announces FDA Clearance of V.A.C.® Therapy for Venous Insufficiency Ulcers
Extends KCI's Reach Across All Three Major Chronic Wound Types
International Consensus Document Offers Greater Clarity on Treatment and Prevention of Pressure Ulcers
New insights from global experts on pressure ulcers to be released at the 20th Conference of the European Wound Management Association (EWMA) in Geneva
KCI to Feature Full Range of Negative Pressure Technology Platform at EWMA
KCI will launch its full range of new NPTP products and support the release of a consensus document on pressure ulcer prevention titled International Review - Pressure, Shear, Friction and Microclimate in Context
KCI Appoints Ron Silverman, M.D., FACS, Chief Medical Officer
Latest Innovation Provides Groundbreaking Design in Negative Pressure Wound Therapy
KCI Appoints Kien Nguyen Vice President of Global Marketing for Active Healing Solutions™
Will Oversee Global Market Development for Negative Pressure Technology Platform
KCI to Feature Unparalleled Range of NPTP Products and Services at SAWC
Negative Pressure Symposium and Conference Exhibit to Focus on KCI's Ongoing Commitment to Improve and Simplify Negative Pressure Treatments
KCI Launches the Prevena™ Incision Management System in Europe and Canada
Prevena™ System First and Only Powered Negative Pressure Product Designed to Manage Incisions at Risk of Complication
KCI Pledges additional Haiti Relief
Disaster has a way of bringing us together. Today KCI has come together as a company to address the significant needs of the people in Haiti. As you know, KCI has been able to donate our products, and now we’d like to help stretch the impact of donations employees may choose to make to the Haiti relief efforts.
KCI Sends Critically Needed Medical Products to Haiti to Help Treat Seriously Wounded
KCI Donates its Signature V.A.C.® Therapy and Other Wound Care Products; In-Kind Donation Valued at More Than $2 Million